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Abstract
Background: Total white blood cell (WBC) count and mean platelet volume have previously 
been shown to predict outcomes in acute coronary syndrome (ACS) patients. In this prospective 
study, we sought to determine the prognostic value of baseline WBC count to mean platelet vol-
ume ratio (WMR) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Methods: A total of 490 patients with NSTE-ACS were prospectively enrolled. The relation-
ship between baseline WMR and major adverse cardiovascular events (MACE) incidence was 
assessed during a mean follow-up of 330.8 ± 38 days.
Results: The patients’ mean age was 60.4 ± 12.9 year, 59% of them were male. The patients 
were categorized into two groups based on WMR values, high- and low-WMR groups (< 755 
vs. ≥ 755). The incidence of MACE was significantly higher in high-WMR compared with 
that of low-WMR group (22.4% vs. 10.7%, p < 0.001). Total WBC counts (median 7.9 vs. 
6.9 ×103/µL, p = 0.004), neutrophil count (median 4.6 vs. 4.2 ×103/µL, p = 0.021), and 
WMR (median 863.2 vs. 731.5, p = 0.001) were significantly higher in the MACE-positive 
than MACE-negative group. The high-WMR was found to be significantly associated with the 
MACE-free survival rate (p < 0.001). In an adjusted cox regression model, the elevated WMR 
was independently predicted the incidence of MACE (hazard ratio 2.419, 95% CI 1.515–3.862, 
p < 0.001).
Conclusions: The elevated baseline WMR independently predicted the MACE incidence in 
patients with NSTE-ACS during long-term follow-up. (Cardiol J 2015; 22, 4: 437–445)
Key words: white blood cell to mean platelet volume ratio, non-ST elevation 
acute coronary syndrome, major adverse cardiovascular events
Introduction
Atherosclerosis has been postulated to be an 
inflammatory disease [1]. Given previous studies, 
acute coronary events are not only attributable 
to the progressive narrowing of coronary artery 
lumen, but also to other pathophysiological fac-
tors involved in the development of such events. 
Atherosclerotic plaques ruptured and contribute to 
thrombus formation by inflammatory mechanisms, 
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through which it can lead to the development of 
acute coronary syndrome (ACS) [2]. 
Leukocytes have been shown to be involved in 
the inflammatory processes, which have potential 
roles in the development of cardiovascular events 
[3]. T-cells and macrophages located in the lipid 
core of an atherosclerotic plaque are activated after 
endothelial injury, and those promote the throm-
bus formation as a result of producing cytokines 
and procoagulants. Therefore, all these processes 
enhance the thrombogenicity and the development 
of ACS [2]. Besides leukocytes, platelets have 
been reported to participate in the development 
of acute coronary events through inflammatory 
pathways [4]. Activated and inactivated platelets 
promote platelet-leukocytes adhesion, including 
adhesion molecules and cytokines, which result 
in the progression of atherogenesis [5]. The in-
teraction between platelets and leukocytes can be 
attributed to the enhancement of leukocyte recruit-
ing at the site of plaque rupture, and this may be 
of great importance in the development of ACS or 
its prognosis [5]. The interactions between these 
cells may be a pathogenic mechanism involved in 
the occlusion of coronary arteries during an ACS 
event [6].
The mean platelet volume, a platelet activation 
marker [7], and leukocyte differentials [8–10] have 
been reported to be associated with cardiovascu-
lar morbidity and mortality. The components of 
complete blood count test have been increasingly 
used in cardiovascular setting and correlated with 
clinical outcomes. Hence, in this prospective study, 
we sought to determine whether the baseline white 
blood cell (WBC) count to mean platelet volume 
ratio (WMR) can predict the long-term outcomes in 
patients with non-ST elevation ACS (NSTE-ACS).
Methods
Study design and population
The present study was conducted in the 
Seyyed-al-Shohada Heart Center of Urmia Univer-
sity of Medical Sciences, Urmia, West-Azerbaijan 
province, Iran, to investigate the prognostic role 
of complete blood count components in the setting 
of ACS. Therefore, 862 consecutive patients who 
had been admitted to the Emergency Department 
with chief complaint of new onset chest discomfort 
were assessed from August 2012 to March 2013. 
A total of 490 patients with a diagnosis of NSTE-ACS 
were enrolled. This study was approved by both 
the local Ethics Committee of Urmia University 
of Medical Sciences and our institutional Review 
Board; and informed consents were obtained from 
all the participants.
All patients complaining of chest discomfort 
were evaluated using full examination, cardiac 
ischemia markers (creatine kinase MB isoenzyme 
[CK-MB] and troponin I), routine biochemical 
markers, and a 12-lead electrocardiogram (ECG). 
Unstable angina was defined as ischemic changes 
in ECG without increasing in cardiac enzymes. 
Non-ST segment elevation myocardial infarc-
tion (NSTEMI) was defined as patients without 
ST-segment elevation in their ECG but with an 
increase in the cardiac ischemia markers. The 
diagnosis of ST-segment elevation myocardial 
infarction (STEMI) was regarded as patients with 
typical ischemic chest pain lasting more than 
20 min associated with one of the features, including 
at least 1 mm ST-segment elevation, a new Q wave, 
a new onset left bundle branch block in ≥ 2 contigu-
ous leads, and/or the elevation of cardiac markers 
at least 2-fold of the maximum normal values. 
A non-ACS patient was considered a case whose 
chest pain was atypical without ischemic changes in 
ECG and/or an increase in cardiac markers. Exclu-
sion criteria included non-ACS patients, STEMI, 
cancer history, inflammatory diseases, autoimmune 
diseases, infectious diseases, and being immuno-
suppressed. Additionally, due to small numbers of 
NSTE-ACS patients undergoing revascularization 
at the time of study conduction, we excluded such 
cases. To identify the incidence of major adverse 
cardiovascular events (MACE), all the patients 
were followed up to December 2013. The patients 
who had unstable angina were given anticoagulants 
(aspirin plus clopidogrel), beta-blocker, angiotensin 
converting enzyme inhibitors, nitrate, and statin. 
The NSTEMI patients were also treated as unsta-
ble angina ones. Furthermore, none of the patients 
underwent revascularization therapy. All blood 
samples were provided at admission and analyzed 
within 30 min of sampling by an automated blood 
cell counter (Sysmex, Kobe, Japan).
Clinical outcomes
All patients were followed for a mean of 330.8 ± 
± 38 days. The measured clinical outcomes were 
as follows: (1) rehospitalization due to unstable 
angina; (2) any kind of cardiac arrhythmias required 
invasive therapies, including long-term consump-
tion of anti-arrhythmic drugs and/or implementing 
implantable cardioverter defibrillator, which were 
continued up to end of follow-up time; (3) non-fatal 
MI; (4) and cardiac death. These endpoints were 
considered a composite MACE (n = 81).
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Statistical analysis
WBC count, mean platelet volume, and WMR 
levels were divided into two groups according to 
their median values as follows: (1) WBC count 
< 7.1 ×103/µL or ≥ 7.1 ×103/µL; (2) mean platelet 
volume < 9.5 fL or ≥ 9.5 fL; and (3) WMR < 755 
or ≥ 755. All continuous variables were reported 
as either median (25th and 75th percentiles) or mean 
± standard deviation and those were analyzed using 
the Mann-Whitney U test or t-test, respectively. 
Categorical variables were reported as number 
(percentage) and compared by the c2 test. The 
receiver operating characteristics (ROC) curve 
analysis was conducted for the detection of di-
agnostic accuracy of biochemical markers. The 
Kaplan-Meier analysis was used to detect the 
MACE-free survival rate, and log-rank test was 
applied to calculate its significance. In addition, 
a multivariate Cox regression analysis, backward 
stepwise model, was used to identify the independ-
ent predictors of composite MACE at follow-up 
period. In this model, all baseline characteristics, 
drug histories, conventional cardiovascular risk 
factors, biomarkers, the status of diagnosis con-
sisting of unstable angina or NSTEMI, and having 
multi-vessel disease were considered covariates, 
and MACE incidence was entered as a dependent 
variable. In the backward stepwise model, p value 
> 0.1 was applied for removing the covariates. 
The values of WBC, mean platelet volume, and 
WMR were entered as categorical variables based 
on their medians, high- vs. low-value. Moreover, 
in an adjusted Cox regression model, all variables 
whose p values were less than 0.05 were entered 
into another model. All statistical analyses were 
performed using SPSS, version 18.0 (SPSS Inc., 
Chicago, IL, USA). A 2-tailed p value less than 0.05 
was considered statistically significant.
Results
Characteristics, clinical features,  
and biomarkers
The patients’ mean age was 60.4 ± 12.9 year, 
and no significant difference was observed between 
the high- and low-WMR groups (p = 0.052); 59% of 
the patients were male (p = 0.069). Heart rate at 
presentation was significantly greater in the high- 
compared with that in low-WMR group (median 
of 80 vs. 78 bpm, p = 0.021). The frequency of 
patients who had NSTEMI was higher in the high-
WMR group than low-WMR group (9% vs. 18.7%, 
p = 0.002). The more proportion of patients in 
the low-WMR group had consumed beta-blockers, 
nitrates, and dual anti-platelet therapy in compari-
son with those in the high-WMR group (Table 1). 
Among laboratories, mean platelet volume was 
significantly lower in the high-WMR compared with 
that in low-WMR group (median of 9.3 vs. 9.8 fL, 
p < 0.001), in contrast, the WBC count was greater in 
high-WMR compared with that in low-WMR group 
(median of 8.8 vs. 6 ×103/µL, p < 0.001). Other 
characteristics and laboratories were summarized 
in the Table 1.
When comparing study variables between 
groups, MACE-positive vs. MACE-negative 
groups, the frequency of hypertension was sig-
nificantly higher in the MACE-positive compared 
with that in the MACE-negative group (66.7% vs. 
54.5%, p = 0.044). Amongst the biomarkers, WBC 
count (median of 7.9 vs. 6.9 ×103/µL, p = 0.004), 
neutrophil count (median of 4.6 vs. 4.2 ×103/µL, 
p = 0.021), and WMR (median of 863.2 vs. 731.5, 
p = 0.001) were significantly higher in the MACE-
-positive compared with those of MACE-negative 
group (Table 2).
In subgroup analysis, patients who were 
younger than 65 years, male, smoker, and diag-
nosed with NSTEMI, had higher WMR values 
compared with patients who were not (Fig. 1).
Diagnostic and survival analysis
According to the ROC curve analysis, the 
area under curve (AUC) for WMR was 0.595 (95% 
confidence interval [CI] 0.519–0.671, p = 0.018), 
and it was found to be higher than those of CK-MB 
and troponin I tests (Fig. 2).
The Kaplan-Meier analysis showed that the 
WMR subgroups (< 755 vs. ≥ 755) were signifi-
cantly associated with the MACE-free survival rate 
(log-rank test p value < 0.001; Fig. 3).
Multivariate analysis
Based on the last step of backward stepwise 
multivariate analysis, male sex (hazard ratio [HR] 
2.689, 95% CI 1.277–5.662, p = 0.009), having 
hypertension (HR 3.780, 95% CI 1.860–7.861, p < 
< 0.001), and a previous use of nitrates (HR 1.954, 
95% CI 1.073–3.558, p = 0.029) were found to be 
the predictors of MACE. Moreover, CK-MB (HR 
1.013, 95% CI 1.001–1.025, p = 0.038), platelet 
count (HR 1.005, 95% CI 1.001–1.009, p = 0.014), 
and hematocrit (HR 0.906, 95% CI 0.839–0.978, 
p = 0.012) were associated with the incidence of 
MACE. Furthermore, the high WMR (HR 2.406, 
95% CI 1.257–4.607, p = 0.008) was found to be 
the strongest marker predicting MACE during 
follow-up (Table 3). In an adjusted model, entering 
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Table 1. Baseline characteristics, laboratories, and long-term outcomes according to white blood cell 
count to mean platelet volume ratio (WMR).
Total
(n = 490)
Low-WMRa
(n = 232)
High-WMRa
 (n = 254)
P
Age [years] 60.4 ± 12.9 61.5 ± 12 59.3 ± 13.7 0.052
Male 289 (59%) 134 (54.9%) 155 (63%) 0.069
Body mass index [kg/m2] 27.7 (24.6, 30.8) 27.7 (24.6, 30.1) 27.7 (24.7, 31.5) 0.593
Heart rate [bpm] 80 (75, 85) 78 (72, 83) 80 (74, 90) 0.021
Systolic BP [mm Hg] 137 (125, 150) 136 (125, 150) 137 (125, 150) 0.870
Diastolic BP [mm Hg] 80 (78, 90) 81.5 (76, 90) 80 (80, 90) 0.917
NYHA: 0.594
Class 1 122 (24.9%) 55 (22.5%) 67 (27.2%)
Class 2 74 (15.1%) 36 (14.8%) 38 (15.4%)
Class 3 265 (54.1%) 139 (57%) 126 (51.2%)
Class 4 29 (5.9%) 14 (5.7%) 15 (6.1%)
Diabetes mellitus 145 (29.6%) 67 (27.5%) 78 (31.7%) 0.303
Hypertension 277 (56.5%) 142 (58.2%) 135 (54.9%) 0.459
Dyslipidemia 87 (17.8%) 40 (16.4%) 47 (19.1%) 0.432
Current smoking 129 (26.3%) 55 (22.5%) 74 (30.1%) 0.058
Familial history 142 (29%) 67 (27.5%) 75 (30.5%) 0.460
Diagnosis: 0.002
Non-ST elevation MI 68 (13.9%) 22 (9%) 46 (18.7%)
Unstable angina 422 (86.1%) 222 (91%) 200 (81.3%)
Multivessel diseaseb 124 (25.3%) 70 (28.7%) 54 (22%) 0.086
Drug histories:
Beta-blockers 226 (46.1%) 130 (53.3%) 96 (39%) 0.002
ACE-I 76 (15.6%) 41 (16.9%) 35 (14.3%) 0.442
Statins 209 (42.7%) 107 (43.9%) 102 (41.5%) 0.593
Nitrates 184 (37.9%) 104 (56.5%) 80 (43.5%) 0.025
Dual anti-platelet 112 (22.9%) 65 (26.6%) 47 (19.1%) 0.047
Biochemical markers:
CK-MB [IU/L] 25 (20, 33) 24 (19, 31) 27 (20, 36) 0.003
Troponin I [ng/µL] 0.01 (0.01, 0.2) 0.01 (0.01, 0.08) 0.01 (0.01, 0.3) 0.005
HDL [mg/dL] 38 (33, 44) 38 (33, 44) 39 (34, 45) 0.202
LDL [mg/dL] 86 (70, 104) 84 (67, 100) 88 (72, 105) 0.051
Blood urea nitrogen [mg/dL] 17.5 (14, 22) 17 (14, 21) 18 (14, 23) 0.158
Creatinine [mg/dL] 0.9 (0.8, 1.1) 0.9 (0.8, 1.1) 0.9 (0.8, 1.1) 0.103
Blood sugar [mg/dL] 107.5 (93, 142) 103 (89, 134.5) 110.5 (95, 146) 0.041
White blood cell count [×103/µL] 7.1 (6, 8.8) 6 (5.3, 6.7) 8.8 (7.8, 10) < 0.001
Neutrophil [×103/µL] 4.3 (3.4, 5.6) 3.5 (3, 4.2) 5.4 (4.3, 7.6) < 0.001
Lymphocyte [×103/µL] 2 (1.5, 2.6) 1.8 (1.5, 2.3) 2.4 (1.7, 2.9) < 0.001
Red blood cell count [×106/µL] 473 (440, 506) 470 (433.5, 499.5) 478.5 (447, 517) 0.017
Hematocrit [%] 41.7 (38.8, 44.9) 41.6 (38.2, 44.3) 41.8 (39.4, 45.6) 0.058
Platelet count [×103/L] 212 (182, 255) 197 (169.5, 228.5) 232 (198, 284) < 0.001
Mean platelet volume [fL] 9.5 (8.9, 10.2) 9.8 (9.2, 10.4) 9.3 (8.7, 9.8) < 0.001
Follow-up features:
   Follow-up duration [day] 336 (309, 360) 336 (309, 366) 333 (300, 360) 0.197
   MACE incidence 81 (16.5%) 26 (10.7%) 55 (22.4%) < 0.001
All values are presented as mean ± standard deviation, median (interquartile range), or number (percentage); aWMR value is categorized  
according to its median, low-WMR < 755 and high-WMR ≥ 755; bMultivessel disease was defined as coronary artery disease ≥ 2 vessels.  
This parameter was available in 360 of patients; ACE-I — angiotensin-converting enzyme inhibitors; BP — blood pressure; CK-MB — creatine 
kinase MB isoenzyme; HDL — high density lipoprotein; LDL — low density lipoprotein; MACE — major adverse cardiovascular events;  
MI — myocardial infarction; NYHA — New York Heart Association
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Table 2. Baseline characteristics and laboratories in groups according to major adverse cardiovascular 
events (MACE) incidence.
MACE-positive
(n = 81)
MACE-negative
(n = 409)
P
Age [years] 60.6 ± 13.1 60.3 ± 12.9 0.875
Male 49 (60.5%) 240 (58.7%) 0.762
Body mass index [kg/m2] 28.3 (25, 30.8) 27.7 (24.6, 30.7) 0.602
Heart rate [bpm] 80 (75, 86) 80 (75, 85) 0.753
Systolic BP [mm Hg] 140 (123, 155) 135 (125, 150) 0.071
Diastolic BP [mm Hg] 82 (80, 90) 80 (77, 90) 0.310
NYHA: 0.479
Class 1 15 (18.5%) 107 (26.2%)
Class 2 15 (18.5%) 59 (14.4%)
Class 3 46 (56.8%) 219 (53.5%)
Class 4 5 (6.2%) 24 (5.9%)
Diabetes mellitus 31 (38.3%) 114 (27.9%) 0.061
Hypertension 54 (66.7%) 223 (54.5%) 0.044
Dyslipidemia 13 (16%) 74 (18.1%) 0.660
Current smoking 24 (29.6%) 105 (25.7%) 0.460
Familial history 23 (28.4%) 119 (29.1%) 0.899
Diagnosis: 0.254
Non-ST elevation MI 8 (11.8%) 60 (17.3%)
Unstable angina 73 (90.1%) 349 (82.7%)
Multivessel disease 21 (25.9%) 103 (25.2%) 0.888
Drug histories:
Beta-blockers 39 (48.1%) 187 (45.7%) 0.689
ACE-I 17 (21%) 59 (14.5%) 0.144
Statins 36 (44.4%) 173 (42.3%) 0.721
Nitrates 35 (43.2%) 149 (36.8%) 0.277
Dual anti-platelet 20 (24.7%) 92 (22.5%) 0.667
Biochemical markers:
CK-MB [IU/L] 27 (20, 33) 24 (20, 33) 0.536
Troponin I [ng/µL] 0.01 (0.01, 0.3) 0.01 (0.01, 0.2) 0.814
HDL [mg/dL] 38.5 (33, 44) 38 (33, 44) 0.792
LDL [mg/dL] 86 (71, 105) 86.5 (68, 96) 0.491
Blood urea nitrogen [mg/dL] 17.5 (14, 22) 18.5 (13.5, 22.5) 0.938
Creatinine [mg/dL] 0.9 (0.8, 1.1) 0.9 (0.8, 1.1) 0.495
Blood sugar [mg/dL] 119 (94, 171) 106 (93, 134) 0.051
White blood cell count [×103/µL] 7.9 (6.7, 9.8) 6.9 (5.9, 8.7) 0.004
Neutrophil [×103/µL] 4.6 (3.9, 6.9) 4.2 (3.4, 5.5) 0.021
Lymphocyte [×103/µL] 2.2 (1.6, 2.7) 2 (1.5, 2.5) 0.308
Red blood cell count [×106/µL] 470 (441, 504) 474 (440, 507) 0.663
Hematocrit [%] 41.4 (38.2, 44.4) 41.8 (38.9, 44.9) 0.105
Platelet count [×103/L] 220 (185, 274) 211 (181, 250) 0.239
Mean platelet volume [fL] 9.5 (8.9, 10) 9.5 (8.9, 10.2) 0.413
WMR 863.2 (687.5, 1012.5) 731.5 (616.8, 924.5) 0.001
Follow-up duration [day] 330 (300, 360) 348 (315, 372) 0.197 
All values are presented as mean ± standard deviation, median (interquartile range), or number (percentage); abbreviations as in Table 1
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Figure 3. Kaplan–Meier curve showing difference be-
tween groups by white blood cell count to mean platelet 
volume ratio (WMR) for major adverse cardiovascular 
events (MACE)-free survival rate.
Figure 1. Comparison of white blood cell count to mean platelet volume ratio (WMR) values in the subgroups. Yes 
— being positive for mentioned variable; No — being negative for mentioned variable. Asterisk showing significant 
differences between paired groups.
Figure 2. Receiver operating characteristics curve iden-
tifying the long-term clinical outcomes; AUC — area 
under curve; CI — confidence interval; rest abbrevia-
tions as in Table 1.
variables with a p value of < 0.05, including hyper-
tension, WBC count, neutrophil count, and WMR, 
the elevated WMR was the strongest independent 
predictor of MACE, as well (HR 2.419, 95% CI 
1.515–3.862, p < 0.001) (Table 3).
Discussion
In this prospective study, we showed, for the 
first time that the elevated baseline WMR was as-
sociated with MACE incidence during long-term 
follow-up in the patients with NSTE-ACS. Being 
male and having hypertension were the independ-
ent predictors of MACE. Moreover, the high-WMR 
was associated with a significant increase in the 
risk of MACE incidence, and it was the strongest 
marker among complete blood count components 
predicting the long-term clinical outcomes.
Traditionally, it has been increasingly reported 
that atherosclerosis develops during the decades 
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of our life. The main factors involved in the devel-
opment of NSTE-ACS include inflammation and 
thrombus formation resulting in the reduction of 
coronary artery flow and resultant ischemia [11]. 
During the rupture of an atherosclerotic plaque, 
platelets adhere to the injured endothelial cells and 
then are activated [4]. The activated ones release 
the inflammatory mediators, express some selectin 
molecules, and secrete cytokines and chemokines 
as well as proinflammatory lipids [4, 5, 12]. The 
adhesion molecules and mediators activate the 
leukocytes [5, 13] and promote the atherothrom-
botic events [5, 14].
Platelets are derived from megakaryocytes 
in the bone marrow, which have been increas-
ingly shown to be involved in the hemostasis and 
maintenance of vascular endothelial integrity [12]. 
Although there are several laboratories to measure 
platelets’ activity, none of them have been consid-
ered in daily clinical practice. The mean platelet 
volume, a platelet activation marker, is a widely 
available and easily measured hematologic test in a 
complete blood cell count test [7], and the elevated 
one has been demonstrated to be associated with 
diabetes mellitus, hypertension, hypercholester-
olemia, and obesity [7]. In addition, it has been 
found to be a diagnostic and prognostic marker in 
patients with ACS or those undergoing percuta-
neous coronary intervention [15–17]. However, 
in a prospective study, no relationship was found 
between increased baseline mean platelet volume 
and the clinical outcomes of patients undergoing 
elective angioplasty, but increases in postoperative 
serial measurements were associated with higher 
mortality rate instead [18]. This study failed to 
find any relationship between elevated baseline 
mean platelet volume and MACE incidence or 
MACE-free survival rate. We think that this may 
be caused by either our population’s feature, which 
only included NSTE-ACS patients rather than high 
risk ones (i.e. STEMI) or its short follow-up dura-
tion, which might be associated with lower number 
of  adverse events. The findings of this study and 
those of Shah et al. [18] underscore the need for 
further investigations regarding the relationship 
between mean platelet volume and the prognosis 
of ACS patients, especially NSTE-ACS cases.
In a longitudinal study, elevated total WBC 
count was associated with high rate mortality [19] 
and the increased risk of cardiovascular diseases 
[20]. Moreover, Sabatine et al. [10] reported that 
an elevated baseline WBC count correlated with 
impaired myocardial perfusion and increased 
6-month mortality in patients diagnosed with 
STEMI. In previous studies concerning the role 
of leukocytes in the prediction of ACS outcomes, 
Table 3. Multivariate Cox regression analysis identifying the predictors of composite major adverse 
cardiovascular events (MACE).
HR 95% CI Pa
Unadjusted model:
Male 2.689 1.277–5.662 0.009
Diabetes mellitus 1.913 0.978–3.738 0.058
Hypertension 3.780 1.860–7.681 < 0.001
Beta-blockers 0.581 0.319–1.056 0.075
Nitrates 1.954 1.073–3.558 0.029
CK-MB 1.013 1.001–1.025 0.038
Blood urea nitrogen 0.951 0.920–0.982 0.002
High density lipoprotein 0.976 0.939–1.014 0.210
Platelet 1.005 1.001–1.009 0.014
Hematocrit 0.906 0.839–0.978 0.012
Mean platelet volume 1.915 0.987–3.714 0.055
WMR 2.406 1.257–4.607 0.008
Adjusted model:b
Hypertension 2.005 1.257–3.198 0.003
WMR 2.419 1.515–3.862 < 0.001
aAll p values of variables in the last step of backward stepwise regression model are listed; bAll variables whose p values were < 0.05 in the 
Table 2 were entered into the second model, adjusted Cox regression model; CI — confidence interval; CK-MB — creatine kinase MB  
isoenzyme; HR — hazard ratio; WMR — white blood cell count to mean platelet volume ratio
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it has been increasingly shown that those can be 
used as prognostic and risk stratification tools in 
such cases, although there have been controver-
sies in terms of the best leukocyte subtype [8–10, 
21]. In this study, we found that WBC count was 
associated with MACE-free survival rate at long-
term follow-up, but it did not predict outcomes. 
These findings are consistent with previous studies 
showing the prognostic role of leukocyte differen-
tials, including total WBC count, neutrophil count, 
lymphocyte, or neutrophil to lymphocyte ratio in 
patients with STEMI [22–25], NSTE-ACS [8], or 
NSTEMI [26]. Although the prognostic value of 
total WBC count has been reported in previous lit-
eratures, the superiority of WMR over WBC count 
was demonstrated in the present study by both 
the stronger probability of MACE-free survival 
rate and the multivariate analysis. We think that 
the ongoing studies concerning the relationship 
between complete blood count components and 
cardiovascular diseases might better clarify this 
notion and identify the best prognostic marker for 
implementation in clinical practice.
The interactions between platelets and leu-
kocytes and vascular endothelial cells at culprit 
lesion have been found to be the main pathophysi-
ologic mechanisms involved in the development 
of atherothrombotic events in the setting of ACS 
[4, 6, 12, 27–29]. Platelet-leukocyte complex assessed 
by flow cytometry has been found as a pathophysi-
ologic mechanism for the development of thrombo-
genesis [6], and monocyte-platelet aggregation was 
also shown as an early marker for acute MI [28] and 
NSTE-ASC patients [30]. Rinder et al. [5] showed 
that this cellular interaction is a dynamic process, 
in which platelet activation status and the ability of 
leukocytes to adhere result in different bindings. 
We should submit that although the elevated mean 
platelet volume is a marker of activated platelets, 
and its increase can contribute to decrease in the 
WMR values, if we consider that the both acti-
vated and inactivated platelets are involved in the 
platelet-leukocyte adhesion, WMR may not differ 
between patients with or without elevated baseline 
mean platelet volume.
Limitations of the study
The main limitation of the study was that we 
did not measure the markers of platelet-leukocyte 
interactions, including selectin molecules [31], ad-
hesion ligands, and receptors [13, 32], which can be 
used as indicative of the platelet-leukocyte inter-
actions. Thus, the evaluation of these biomarkers 
along with WMR may confirm causality. In addition, 
the small sample size of our study is another limi-
tation; further large scale studies among STEMI 
patients and those undergoing angioplasty will be 
useful in order to prove these preliminary findings. 
Furthermore, we did not consider revascularization 
procedures developed during follow-up a MACE; 
hence, it may be associated with outcomes and 
provides further information with respect to any 
relationship between the WMR values of patients 
being revascularized and their outcomes. On the 
other hand, this shortcoming cannot be interfered 
with our findings showing the WMR as a prognos-
ticator of long-term outcomes.
Conclusions
An elevated baseline WMR value was associ-
ated with clinical outcomes in patients with NSTE-
-ACS, and independently predicted the MACE 
incidence even stronger than other complete blood 
count components, including leukocyte differen-
tials, platelet indices, and red blood cell indices.
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